MedCity News November 26, 2024
Roche is acquiring Poseida Therapeutics, a biotech developing allogeneic cell therapies for cancers and immunological indications. The two companies have been partners in hematological malignancies since 2022.
Roche, already partnered with Poseida Therapeutics in the development of off-the-shelf cell therapies for blood cancers, is broadening its ambitions with the modality through a deal to acquire the biotech for $1 billion up front.
Applying allogeneic cell therapies to solid tumors and immunological indications are among the goals Roche aims to achieve by buying San Diego-based Poseida. According to deal terms announced Tuesday, Roche will pay $9 in cash for all shares of the biotech. That price represents a 215% premium to Posedia’s closing stock price on Monday. When Poseida went public...
Today's Sponsors
Today's Sponsor